Trials / Completed
CompletedNCT02075281
Effect of LAPS-Exendin on Body Weight in Obese Population
A 20-week, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial to Assess the Safety and Efficacy of HM11260C on Body Weight in Obese Subjects Without Diabetes
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 297 (actual)
- Sponsor
- Hanmi Pharmaceutical Company Limited · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine the optimal dose and regimen of HM11260C, in combination with a hypocaloric diet, to reduce weight in obese subjects who are otherwise considered in stable health.
Detailed description
Phase 2 study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | HM11260C | Glucagon-like peptide-1 analogue |
| BIOLOGICAL | Placebo |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2015-01-01
- Completion
- 2015-02-01
- First posted
- 2014-03-03
- Last updated
- 2016-08-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02075281. Inclusion in this directory is not an endorsement.